Sign in
4

Changes in Ownership

Contineum Therapeutics, Inc. Filed Acc 0001437749-26-006421

CMO & Head of Development sold 3,611 shares at $15.02 ($54,220)

  • CMO & Head of Development acquired 3,611 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Watkins Tim · CMO & Head of Development

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2026-03-02 Exercise or conversion : show line 1 in the form 10b5-1 +3,611 $4.50 $16,250 3,611 D
2026-03-02 Sale : show line 2 in the form 10b5-1 −3,611 $15.02 $54,220 0 D
Open-market sales · 3,611 sh · avg $15.02 · $54,220

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2026-03-02 Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) −3,611 249,167 D
Loading xslF345X05/rdgdoc.xml…